Upfront riociguat and ambrisentan combination therapy for newly diagnosed pulmonary arterial hypertension: A prospective open-label trial
Jason Weatherald, Mitesh V. Thakrar, Rhea Varughese, Mithum Kularatne, Jonathan Liu, Lea Harper, Omid Kiamanesh, Nowell M. Fine, Evan Orlikow, Chidera Nwaroh, Christina S. Thornton, John R. Swiston, L. Kolkman, Nathan W. Brunner, Doug Helmersen, Naushad Hirani
Topics & Concepts
AmbrisentanRiociguatMedicineTolerabilityInternal medicinePulmonary hypertensionClinical endpointProspective cohort studyCardiologyChronic thromboembolic pulmonary hypertensionClinical trialEndothelin receptorAdverse effectBosentanReceptorPulmonary Hypertension Research and TreatmentsBlood Pressure and Hypertension StudiesPhosphodiesterase function and regulation